Small caps round-up: Cyprotex, Noble Investments, Accumuli

published 16 October 2012

Cyprotex rose over three per cent after it said it had signed a licensing agreement with Sigma Life Science. Cyprotex will add Sigma's CompoZr Zinc Finger Nuclease technology to its screening services in an agreement that marks the first non-exclusive licence granted by Sigma for the technology.

Noble Investments, the international rare coin and stamp dealer and auctioneer, said its auction business, Baldwin's, was owed £2.2m in commission after "a significant Qatari collector" had failed to pay the bill its services. The collector is yet to receive the coins purchased but the news pushed shares down 5.7%. The firm said it was taking legal advice on the matter. Noble also said it was on track to meet full year expectations.

Accumuli, a provider of IT security services, said trading in the six months to the end of September was in line with management expectations despite the wider adverse macro economic climate. The group said it continued to achieve strong cash generation. After acquisition costs and the initial £0.9m payout for EdgeSeven, which it bought in June, the firm said it had a cash pile of £1.5m.